Bonti to Present at Piper Jaffray 29th Annual Healthcare Conference

Bonti to Present at Piper Jaffray 29th Annual Healthcare Conference

Fauad Hasan, Co-founder and CEO, to Provide Bonti Highlights on November 29th in New York City

Bonti, a privately-held, clinical-stage biotechnology company, today announced that Fauad Hasan, co-founder and CEO, is scheduled to present at the Piper Jaffray 29th Annual Healthcare Conference. The conference is taking place November 28th and 29th at the Lotte New York Palace Hotel in New York City, NY.

Mr. Hasan will provide an overview of the Company’s technology and strategy during his presentation on Wednesday, November 29th at 11:30 AM (ET). He will spotlight Bonti’s lead product candidate, EB-001, which is a novel botulinum neurotoxin with a unique target profile, characterized by fast onset of action and short duration of effect. The clinical safety and efficacy of EB-001 is being investigated in Phase 2 clinical trials, including in the Company’s LANTERN-1 pain study, as part of its development arc for therapeutic and aesthetic indications with significant addressable market opportunities.

“We are delighted that Bonti will be participating in the Piper Jaffray Healthcare Conference again this year,” said Fauad Hasan, co-founder and CEO. “We’re grateful to Piper Jaffray for the opportunity to share our compelling opportunity with the broad investment community. We look forward to summarizing the success and progress to date of the clinical programs for our lead candidate, EB-001, and to outlining our exciting plans for 2018.”

About EB-001
Bonti’s lead product candidate, EB-001, is an investigational botulinum neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed botulinum neurotoxin serotype A (BoNT/A) products though it has a differentiated clinical profile. EB-001 has a fast onset of action (within 24 hours) and a short duration of effect (about 4 weeks). Currently marketed BoNT/A products have an onset of action of 3 – 7 days and a duration of effect of 3 – 4 months. The unique target clinical profile of EB-001 may be well suited for a vast range of aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain, with currently unmet needs.

About Bonti
Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin and biologics experts with proven prior success at Allergan and Halozyme. This team, with deep neurotoxin, aesthetic and pain expertise, is uniquely qualified to develop treatment paradigms driven by a novel neurotoxin platform designed to become an innovative leader in both aesthetic and therapeutic markets. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti seeks to improve lives by successfully addressing key unmet needs.

For more information, please visit http://bonti.com.

Contact
Orlando Rodrigues
Media Relations
orlando@bonti.com
760.212.5727

2018-05-03T21:03:24+00:00 November 27th, 2017|Press Releases|